Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer

医学 安慰剂 便秘 内科学 临床终点 胃肠病学 不利影响 随机对照试验 临床研究阶段 类阿片 临床试验 受体 病理 替代医学
作者
Nobuyuki Katakami,Toshiyuki Harada,Tōru Murata,Katsunori Shinozaki,Masakazu Tsutsumi,Takaaki Yokota,Masatsugu Arai,Yukio Tada,Masaru Narabayashi,Narikazu Boku
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (34): 3859-3866 被引量:138
标识
DOI:10.1200/jco.2017.73.0853
摘要

Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer. Patients and Methods This phase III trial consisted of a 2-week, randomized, double-blind, placebo-controlled study (COMPOSE-4) and an open-label, 12-week extension study (COMPOSE-5). In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned on a 1:1 basis to receive once-daily oral naldemedine 0.2 mg or placebo. The primary end point was the proportion of spontaneous bowel movement (SBM) responders (≥ 3 SBMs/week and an increase of ≥ 1 SBM/week from baseline). The primary end point of COMPOSE-5 was safety. Results In COMPOSE-4, 193 eligible patients were randomly assigned to naldemedine (n = 97) or placebo (n = 96). The proportion of SBM responders in COMPOSE-4 was significantly greater with naldemedine than with placebo (71.1% [69 of 97 patients] v 34.4% [33 of 96 patients]; P < .0001). A greater change from baseline was observed with naldemedine than with placebo in the frequency of SBMs/week (5.16 v 1.54; P < .0001), SBMs with complete bowel evacuation/week (2.76 v 0.71; P < .0001), and SBMs without straining/week (3.85 v 1.17; P = .0005). In COMPOSE-4, more patients treated with naldemedine than with placebo reported treatment-emergent AEs (TEAEs) (44.3% [43 of 97 patients] v 26.0% [25 of 96 patients]; P = .01); in COMPOSE-5, 105 (80.2%) of 131 of patients reported TEAEs. Diarrhea was the most frequently reported TEAE in COMPOSE-4 (19.6% [19 of 97 patients] v 7.3% [seven of 96 patients] with naldemedine v placebo) and COMPOSE-5 (18.3% [24 of 131 patients] with naldemedine). Naldemedine was not associated with signs or symptoms of opioid withdrawal and had no notable impact on opioid-mediated analgesia. Conclusion Once-daily oral naldemedine 0.2 mg effectively treated OIC and was generally well tolerated in patients with OIC and cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci的应助被江江采纳,获得10
1秒前
1秒前
Leakki发布了新的文献求助10
1秒前
2秒前
pajamsleep完成签到,获得积分10
2秒前
龙傲天完成签到,获得积分10
2秒前
Amber发布了新的文献求助10
2秒前
2秒前
小童完成签到,获得积分10
3秒前
Ava的应助被111采纳,获得10
3秒前
3秒前
安医清嘉发布了新的文献求助10
4秒前
Tuniverse_发布了新的文献求助10
4秒前
4秒前
yiyi完成签到,获得积分10
4秒前
4秒前
人类懂王完成签到,获得积分20
4秒前
5秒前
awei发布了新的文献求助10
5秒前
6秒前
zxiaoo完成签到,获得积分10
6秒前
赖东东完成签到,获得积分10
6秒前
xx发布了新的文献求助10
6秒前
桐桐的应助被ndj采纳,获得10
6秒前
7秒前
7秒前
7秒前
212完成签到,获得积分10
7秒前
nxy完成签到 ,获得积分10
7秒前
Jelly完成签到,获得积分10
7秒前
Doolin完成签到,获得积分10
7秒前
袁气奶豆发布了新的文献求助20
8秒前
兰先生完成签到 ,获得积分10
8秒前
asl完成签到 ,获得积分10
8秒前
c皮皮发布了新的文献求助10
8秒前
reaaa完成签到 ,获得积分10
9秒前
Lees完成签到,获得积分10
9秒前
nnn发布了新的文献求助10
9秒前
HYXin完成签到,获得积分20
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182178
求助须知:如何正确求助?哪些是违规求助? 9571839
关于积分的说明 21820273
捐赠科研通 7778694
什么是DOI,文献DOI怎么找? 3433632
关于科研通互助平台的介绍 2557802
邀请新用户注册赠送积分活动 2479657